Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13954197 | 0.84 | TERT (0.71) | TERT | |
| SCHEMBL13587915 | 0.78 | TERT (0.64) | TERT | |
| SCHEMBL805247 | 0.74 | TERT (0.56) | TERT | |
| SCHEMBL14307852 | 0.67 | TERT (0.50) | TERT | |
| SCHEMBL800451 | 0.56 | TERT (0.37) | TERT | |
| SCHEMBL12299121 | 0.46 | — | — | |
| SCHEMBL11957235 | 0.45 | CCR1 (0.59) | — | |
| SCHEMBL2089931 | 0.44 | KDM4E (0.56) | — | |
| SCHEMBL24921366 | 0.43 | PTGDR (0.39) | — | |
| SCHEMBL1200783 | 0.42 | CCR1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250283075-A1 | COMPOSITIONS FOR TARGETING FLI-1 AND METHODS OF USE THEREOF | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4543854-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-115490708-B | Sulfonamide macrocyclic derivative, preparation method and application thereof | 苏州亚盛药业有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2023250058-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-116964061-A | Tricyclic pyrimidines as cyclin dependent kinase 7 (CDK 7) inhibitors | 詹森药业有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116234931-A | Bicyclic conjugates with specificity for NECTIN-4 and uses thereof | 拜斯科技术开发有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-4161575-A1 | CRYSTALLINE FORMS OF IRAK DEGRADERS | Kymera Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2023028605-A1 | COMPOSITIONS FOR TARGETING FLI-1 AND METHODS OF USE THEREOF | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT D/B/A ZUCKER INSTITUTE FOR INNOVATION COMMERCIALIZATION (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-115490708-A | Sulfonamide macrocyclic derivatives, and preparation method and application thereof | 苏州亚盛药业有限公司 | 2022-12-20 | — | — | CN | disclosed |
| US-20220380362-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2022-12-01 | — | — | US | disclosed |
| US-20120046234-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2012-02-23 | — | — | US | disclosed |
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2011-09-22 | — | — | US | disclosed |
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2011-09-22 | — | — | US | disclosed |
| US-20100249175-A1 | Dicationic compounds which selectively recognize G-quadruplex DNA | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249175-A1 | Dicationic compounds which selectively recognize G-quadruplex DNA | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7470714-B2 | GM-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent | SOSEI CO., LTD. (JP) | 2008-12-30 | — | — | US | disclosed |
| US-7470714-B2 | GM-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent | SOSEI CO., LTD. (JP) | 2008-12-30 | — | — | US | disclosed |
| EP-1792613-A2 | Dicationic compounds which selectively recognize G-quadruplex DNA | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-06-06 | — | — | EP | disclosed |
| US-7192763-B2 | Streptomyces anulatus microorganism and a process for producing the substance GM-95 | SOSEI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192763-B2 | Streptomyces anulatus microorganism and a process for producing the substance GM-95 | SOSEI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249175-A1 | Dicationic compounds which selectively recognize G-quadruplex DNA | DDB1, DNA2, SSBP1 | TERT 543/4885 |
| US-20220380362-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TERT 134/4885 |
| US-20250283075-A1 | COMPOSITIONS FOR TARGETING FLI-1 AND METHODS OF USE THEREOF | FLI1, GAP43, FLNA | TERT 2440/4885 |
| US-20120046234-A1 | THERAPEUTIC COMPOUNDS | MKI67, MCL1, TP53 | TERT 281/4885 |
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | MCL1, MKI67, NCL | TERT 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.